Jaguar Health, Inc. (JAGX)
NASDAQ: JAGX · Real-Time Price · USD
0.591
-0.012 (-1.94%)
At close: Mar 6, 2026, 4:00 PM EST
0.580
-0.011 (-1.80%)
After-hours: Mar 6, 2026, 7:26 PM EST
Jaguar Health Employees
Jaguar Health had 49 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
49
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$240,510
Profits / Employee
-$822,306
Market Cap
2.68M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Scinai Immunotherapeutics | 31 |
| Dermata Therapeutics | 8 |
| Enveric Biosciences | 6 |
| Artelo Biosciences | 5 |
| Oragenics | 5 |
| GRI Bio | 4 |
| 60 Degrees Pharmaceuticals | 3 |
| PMGC Holdings | 3 |
JAGX News
- 4 days ago - Jaguar Health Secures an Additional $3 Million Payment from Future Pak for Mytesi and Canalevia-CA1 - Accesswire
- 5 days ago - Reminder: Today, March 2, 2026, is the Record Date for Jaguar Health's Special One-time Stock Dividend - Accesswire
- 17 days ago - Jaguar Health Announces a Special One-time Stock Dividend - Accesswire
- 6 weeks ago - Jaguar Health Highlights Sharp Strategic Focus on Rare Intestinal Failure Diseases Fueled by Non-Dilutive Funds from Closing of License Deal for Mytesi - Accesswire
- 7 weeks ago - Jaguar Health Presenting January 15 at Lytham Partners Healthcare Investor Summit to Provide Updates on Near-Term Catalysts - Accesswire
- 7 weeks ago - Jaguar Health Enters into U.S. License Agreement with Future Pak for Crofelemer, Providing up to $38 Million - Accesswire
- 2 months ago - Article About Groundbreaking Results from Study of Jaguar Health's Crofelemer for Treatment of Intestinal Failure Featured in United Arab Emirates Healthcare Publication - Accesswire
- 2 months ago - Jaguar Health Awarded $240,000 FDA Grant in Support of Canalevia-CA1 for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs - Accesswire